Tempus AI Earns Dual Analyst Upgrades With $76-$80 Price Targets on Platform Potential

Tempus AI's Data Business Is Priced Like a Vendor, Not a Platform, Analyst Says - Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) stock is trading lower on Wednesday, even after Cantor Fitzgerald initiated coverage with an Overweight rating and set a price target of $80. Analyst Sarah James says the market undervalues Tempus' Data & Applications business by treating it as a life sciences data vendor, despite growth and margins more comparable to a platform business. The analyst writes that, like DDOG and SNOW, Tempus sells data and AI tools to 19 of the 20 largest pharmaceutical companies and more than 250 biotechs across their R&D pipelines. This allows TEM to benefit from overall biopharma activity rather than relying on any individual drug or trial. Tempus also follows a "one-cart" model with providers, with a single relationship spanning hereditary risk testing, CGP therapy selection, MRD monitoring and rare-disease sequencing across more than 100 assays, despite their differing clinical applications, adds the analyst. Strong Revenue Growth Prospects The analyst says that Tempus' growth could be driven by five underappreciated catalysts, potentially supporting revenue above the $2.4 billion 2028 estimate versus $1.3 billion in 2025. Trending CGP volumes could nearly double as physician adoption expands beyond 40%-50%, while xT CDx migration and xF reimbursement could lift therapy-selection ASPs more than 40%, from about $1,850 to over $2,600, adds the analyst. MRD, a roughly $20 billion opportunity, and the hereditary-testing gap offer additional growth avenues, with MRD volumes already up 38% quarter over quarter in the second quarter, adds the analyst. Management estimates algorithmic diagnostics could create 50-100x their cost in value, representing another potential upside opportunity that the market may be underappreciating. TEM Stock Price Activity: Tempus AI shares were down 2.18% at $60.91 on Wednesday, according to Benzinga Pro data. Cathie Wood Sells $15.6 Million of Tempus AI Stock After Merck-Moderna Trial Win, Ark Keeps Selling AMD Shares Ark Invest sold $15.6 million of Tempus AI and $3.4 million of AMD on Tuesday, Sept. 1, 2026. 2 min read Read this article Photo via Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Piper Sandler upgrades Tempus AI stock rating on acquisition benefits By Investing.com

Investing.com - Piper Sandler upgraded Tempus AI Inc (NASDAQ:TEM) to Overweight from Neutral on Monday and raised its price target to $76 from $56. With shares currently trading at $63.05, the new target implies roughly 20% upside potential. Analyst price targets range from $35 to $100, reflecting divergent views on the company's $11.4 billion market valuation. The firm cited three growth drivers that have become more visible for the diagnostics and data company. The pending acquisition of Personalis gives Tempus ownership of a differentiated tumor-informed MRD platform, according to the firm. The positive INTerpath-001 readout increases the strategic value of Personalis and Tempus AI's role as the tumor sequencing provider for potentially a new therapeutic class, Piper Sandler said. The company's momentum is reflected in its 50% revenue growth over the last twelve months. According to InvestingPro data, 6 analysts have revised their earnings upwards for the upcoming period, though the platform's Fair Value analysis suggests the stock may be overvalued at current levels. Investors seeking deeper insights can access comprehensive analysis through TEM's Pro Research Report, available for this and 1,400+ other US equities. FDA approval of tumor-only xT CDx clears a key hurdle for Tempus to pursue unified ADLT pricing for xT, the firm noted. The xF product could potentially follow in the second half of 2027. Piper Sandler's previous Neutral rating reflected a stock valuation that was being driven more by AI sentiment and was not correlating with the performance of its diagnostics and data businesses, the firm said. In other recent news, Tempus AI reported its second-quarter 2026 financial results, revealing a narrower-than-expected loss with adjusted earnings per share at negative $0.04, outperforming analysts' estimates of a negative $0.08. Revenue for the quarter rose by 22% year-over-year to $382.5 million, though it fell short of some projections, such as H.C. Wainwright's expectation of $390.9 million. The quarter marked the first full period since Tempus AI's acquisition of Ambry Genetics, which contributed to the revenue growth. Additionally, Tempus AI is proceeding with its acquisition of Personalis, as detailed in a recent S-4 filing. Canaccord Genuity reiterated a Buy rating with an $80 price target, emphasizing potential synergies from this acquisition. Meanwhile, BTIG and H.C. Wainwright both adjusted their price targets to $70 and $56, respectively, while maintaining Buy ratings. Stifel lowered its price target to $50, citing concerns over margins despite positive oncology volume growth and regulatory approvals. These developments highlight ongoing strategic moves and financial performance for Tempus AI. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Cantor Fitzgerald Initiates Tempus AI at Overweight With $80 Price Target

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

Piper Sandler Upgrades Tempus AI to Overweight From Neutral, Adjusts PT to $76 From $56

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.